Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073867 | 0.85 | SMN1; SMN2 (0.45) | FLT3HDAC6CDK2PRKAG1PRKAA1 | |
| SCHEMBL176882 | 0.84 | PRKAG1 (0.66) | FLT3CDK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL13931749 | 0.83 | TUBB1 (0.61) | RAB9ANPC1L3MBTL1CASP3SENP8 | |
| SCHEMBL14001681 | 0.83 | TUBB1 (0.52) | FLT3CDK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL4482588 | 0.83 | FLT3 (0.65) | FLT3CDK2ALDH1A1HRH1RAB9A | |
| SCHEMBL18554248 | 0.81 | BCHE (0.56) | FLT3CYP3A4HDAC6CDK2PRKAG1 | |
| SCHEMBL10073860 | 0.81 | PRKAG1 (0.44) | FLT3KMT2AHDAC6CDK2PRKAG1 | |
| SCHEMBL17782665 | 0.81 | FLT3 (0.47) | FLT3TSHRKMT2AMEN1CDK2 | |
| SCHEMBL14387460 | 0.80 | TUBB1 (0.49) | FLT3CDK2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL13794487 | 0.80 | L3MBTL1 (0.47) | FLT3KMT2AMEN1HDAC6CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562909-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK SHARP & DOHME (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7563816-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563816-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1663987-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7410992-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-7410992-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080032951-A1 | Ophthalmic Compositions For Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-02-07 | — | — | US | disclosed |
| US-20080032951-A1 | Ophthalmic Compositions For Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2008-02-07 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-01-11 | — | — | US | disclosed |
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010491-A1 | Ophthalmic compositions for treating ocular hypertension | REN, KCNH2, KCNH3 | CYP1A2 2787/4885FLT3 4764/4885TSHR 1299/4885 |
| US-20080032951-A1 | Ophthalmic Compositions For Treating Ocular Hypertension | KCNH2, KCNN1, KCNH3 | CYP1A2 2584/4885FLT3 4646/4885TSHR 3591/4885 |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | CYP1A2 2713/4885FLT3 4484/4885TSHR 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.